Falcarindiol from Angelica koreana Down-regulated IL-8 and Up-regulated IL-10 in Colon Epithelial Cells.
10.20307/nps.2017.23.2.103
- Author:
Sun Yup SHIM
1
;
Seul gi LEE
;
Mihye KIM
;
Jin Woo LEE
;
Bang Yeon HWANG
;
Mina LEE
Author Information
1. College of Pharmacy, Sunchon National University, Suncheon 57922, Jeonnam, Republic of Korea. minalee@sunchon.ac.kr
- Publication Type:Original Article
- Keywords:
Angelica koreana;
Falcarindiol;
Inflammatory bowel disease;
Colon epithelial cells
- MeSH:
Angelica*;
Blotting, Western;
Colon*;
Epithelial Cells*;
Far East;
Immune System;
Inflammation;
Inflammatory Bowel Diseases;
Interleukin-10*;
Interleukin-8*;
Korea;
Methanol;
Nitric Oxide Synthase Type II;
Plants, Medicinal;
Prostaglandin-Endoperoxide Synthases
- From:Natural Product Sciences
2017;23(2):103-107
- CountryRepublic of Korea
- Language:English
-
Abstract:
Angelica koreana is an important medicinal plant for some locals in East Asia including Korea. A few reports have shown the efficacy of its phytochemical constituents. We have isolated and purified one compound falcarindiol (FAL) from the methanolic extract of A. koreana roots. At concentrations from to 1 µM to 25 µM, the FAL isolated from the roots of A. koreana exerted no significant cytotoxicity and down-regulated LPS-stimulated pro-inflammatory cytokine IL-8 in colon epithelial cells, while up-regulating anti-inflammatory cytokine IL-10. In addition, the FAL decreased the expression of LPS-induced inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 protein by Western blot analysis. Colon epithelial cells play pivotal roles in regulating the colon immune system and thus FAL is expected to be candidate agent as therapeutic potential for the treatment of inflammatory bowel disease (IBD) by modulating LPS-induced inflammation in colon epithelial cells.
